Top

Annals of Hematology

Published in:

08-02-2023 | Multiple Myeloma | Letter to the Editor

Early leukoencephalopathy during daratumumab treatment in a patient with multiple myeloma

Authors: Shanshan Liu, Hongwei Zhou, Weiling Xu, Tao Jin, Xinyue Liang, Xiaoxia Zhao, Yun Dai, Fengyan Jin

Published in: Annals of Hematology | Issue 4/2023

Excerpt

Dear Editor, …

Available only for authorised users

Köhler W, Curiel J, Vanderver A (2018) Adulthood leukodystrophies. Nat Rev Neurol 14:94–105. https://doi.org/10.1038/nrneurol.2017.175CrossRefPubMed

Chari A, Attaya Suvannasankha A, Fay JW et al (2017) Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood 130:974–981. https://doi.org/10.1182/blood-2017-05-785246CrossRefPubMedPubMedCentral

Monge J, Contreras J, Elsoukkary S et al (2019) Progressive multifocal leukoencephalopathy in a patient with multiple myeloma receiving daratumumab and pomalidomide. Blood 134:4876. https://doi.org/10.1182/blood-2019-122134CrossRef

Kareem SS, Viswanathan N, Sahebjam S et al (2022) Leukoencephalopathy during daratumumab-based therapy: a case series of two patients with multiple myeloma. Onco Targets Ther 15:953–962. https://doi.org/10.2147/OTT.S365657CrossRefPubMedPubMedCentral

Santomasso BD, Nastoupil LJ, Adkins S et al (2021) Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol 39:3978–3992. https://doi.org/10.1200/JCO.21.01992CrossRefPubMed

Mohyuddin GR, Mian H (2022) Daratumumab in newly diagnosed MM — incorporating lessons learnt from CASSIOPEIA, MAIA and beyond. Nat Rev Clin Oncol 19:3–4. https://doi.org/10.1038/s41571-021-00581-2CrossRefPubMed

Kastritis E, Palladini G, Minnema MC et al (2021) Daratumumab-based treatment for immunoglobulin light-chain amyloidosis. N Engl J Med 385:46–58. https://doi.org/10.1056/NEJMoa2028631CrossRef

Hattori T, Kaji M, Ishii H et al (2017) CD38 positively regulates postnatal development of astrocytes cell-autonomously and oligodendrocytes non-cell-autonomously. Glia 65:974–989. https://doi.org/10.1002/glia.23139CrossRefPubMed

Vercruyssen M, Hachem GE, Maerevoet M (2018) The daratumumab crosses the blood brain barrier. Clin Lymph Myelo Leuk 18:S289. https://doi.org/10.1016/j.clml.2018.07.229CrossRef

10.

Guerreiro S, Privat A-L, Bressac L et al (2020) CD38 in neurodegeneration and neuroinflammation. Cells 9:471. https://doi.org/10.3390/cells9020471CrossRefPubMedPubMedCentral

Title: Early leukoencephalopathy during daratumumab treatment in a patient with multiple myeloma
Authors: Shanshan Liu
Hongwei Zhou
Weiling Xu
Tao Jin
Xinyue Liang
Xiaoxia Zhao
Yun Dai
Fengyan Jin
Publication date: 08-02-2023
Publisher: Springer Berlin Heidelberg
Keywords: Multiple Myeloma
Cranial MRI
Daratumumab
Hematologic Cancer
Dexamethasone
Published in: Annals of Hematology / Issue 4/2023
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-023-05120-w

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2023

Tocilizumab, an IL6-receptor antibody, proved effective as adjuvant therapy for cytokine storm induced by severe infection in patients with hematologic malignancy

Maternal factors associated with iron deficiency without anaemia in early pregnancy: ECLIPSES study

Impact of gemtuzumab ozogamicin consolidation on hematopoietic stem cells (HSCs) mobilization in AML: analysis of 20 patients

Ibrutinib in relapsed/refractory patients with Waldenström macroglobulinemia: a real-life, retrospective study on behalf of the “RTL” (regional Tuscan lymphoma network)

Real-world outcomes of adult patients with acute lymphoblastic leukemia treated with a modified CALGB 10102 regimen

How I manage anemia related to myelofibrosis and its treatment regimens

Keynote webinar | Spotlight on antibody–drug conjugates in cancer